Molecular docking analysis of piperlongumine with different apoptotic proteins involved in Hepatocellular Carcinoma.
AutoDock
Hepatocellular Carcinoma
Molecular Docking
Piperlongumine
Vascular Endothelial Growth Factor
Journal
Bioinformation
ISSN: 0973-2063
Titre abrégé: Bioinformation
Pays: Singapore
ID NLM: 101258255
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
07
2021
revised:
21
09
2021
accepted:
21
09
2021
entrez:
11
5
2022
pubmed:
12
5
2022
medline:
12
5
2022
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Numerous signalling pathways are involved in hepatocellular carcinoma. Piperlongumine is a potential candidate for the treatment of hepatocellular carcinoma. Therefore, it is of interest to document the molecular docking analysis of piperlongumine with different apoptotic proteins involved in Hepatocellular Carcinoma. Piperlongumine was docked with the HCC targets such as vascular endothelial growth factor (VEGF), epidermal growth factor receptor, Aurora-2, Nuclear factor Kappa-B (NF-KB), Jak2 Kinase, Fibroblast growth factor receptor 4, Bcl-2-like protein 1,Apopain, and Apoptosis regulator Bcl-2 using
Identifiants
pubmed: 35539886
doi: 10.6026/97320630017829
pii: 97320630017829
pmc: PMC9049083
doi:
Types de publication
Journal Article
Langues
eng
Pagination
829-833Informations de copyright
© 2021 Biomedical Informatics.
Références
Indian J Cancer. 2017 Jul-Sep;54(3):526-529
pubmed: 29798951
Pharmacogn Mag. 2016 May;12(Suppl 3):S350-2
pubmed: 27563224
PLoS One. 2015 Dec 08;10(12):e0143964
pubmed: 26645674
Nat Rev Gastroenterol Hepatol. 2017 Sep;14(9):527-539
pubmed: 28676707
J Biol Chem. 2017 Jan 6;292(1):112-120
pubmed: 27872191
J Clin Exp Hepatol. 2020 Jan-Feb;10(1):43-80
pubmed: 32025166
Mol Cancer Ther. 2014 Oct;13(10):2422-35
pubmed: 25082961
J Chem Inf Model. 2018 Aug 27;58(8):1697-1706
pubmed: 29989806
J Chem Inf Model. 2012 Nov 26;52(11):3099-105
pubmed: 23092397
Pharmacol Res. 2020 Jun;156:104772
pubmed: 32283222
Eur J Pharm Sci. 2013 Feb 14;48(3):453-63
pubmed: 23238172
Nucleic Acids Res. 2016 Jan 4;44(D1):D1202-13
pubmed: 26400175
Oncotarget. 2015 Mar 20;6(8):6406-21
pubmed: 25788268